The GLP-1 RA user group demonstrated a reduced hazard ratio (HR, 95 % confidence interval) over 5 years compared with the DPP4i user group for all-cause mortality (0.62, 0.59–0.66, P < 0.001), all-cause hospitalization (0.71, 0.69–0.73, P < 0.001), acute myocardial infarction (0.87, 0.82–0.92, P < 0.001), heart failure exacerbation (0.83, 0.81–0.86, P < 0.001) and cerebrovascular accidents (0.85, 0.80–0.92, P < 0.001). The gene discussed is GLP1R; the disease is heart failure.